283 related articles for article (PubMed ID: 17934259)
21. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.
Hung KH; Sheu BS; Chang WL; Wu HM; Liu CC; Wu JJ
Helicobacter; 2009 Feb; 14(1):61-5. PubMed ID: 19191898
[TBL] [Abstract][Full Text] [Related]
22. Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant.
Sierra JM; Ortega M; Tarragó C; Albet C; Vila J; Terencio J; Guglietta A
J Antimicrob Chemother; 2009 Nov; 64(5):990-2. PubMed ID: 19717395
[TBL] [Abstract][Full Text] [Related]
23. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea.
Kim JY; Kim SH; Jeon SM; Park MS; Rhie HG; Lee BK
Clin Microbiol Infect; 2008 Aug; 14(8):760-5. PubMed ID: 18727800
[TBL] [Abstract][Full Text] [Related]
24. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Luo T; Yuan J; Peng X; Yang G; Mi Y; Sun C; Wang C; Zhang C; Bao L
J Antimicrob Chemother; 2017 Jul; 72(7):1893-1900. PubMed ID: 28387828
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of the mycobacterium efficacy of linezolid in vitro].
Huang HR; Yu X; Jiang GL; Dai GM; Bi ZQ; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Aug; 34(8):575-8. PubMed ID: 22168977
[TBL] [Abstract][Full Text] [Related]
26. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
27. Role of novel gyrA mutations in the suppression of the fluoroquinolone resistance genotype of vaccine strain Salmonella Typhimurium vacT (gyrA D87G).
Preisler A; Mraheil MA; Heisig P
J Antimicrob Chemother; 2006 Mar; 57(3):430-6. PubMed ID: 16431864
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.
Pumbwe L; Chang A; Smith RL; Wexler HM
J Antimicrob Chemother; 2006 Sep; 58(3):543-8. PubMed ID: 16840432
[TBL] [Abstract][Full Text] [Related]
29. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.
Rodriguez Díaz JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2003 Apr; 21(4):354-6. PubMed ID: 12672583
[TBL] [Abstract][Full Text] [Related]
30. [The effects of gene mutation related to drug resistance and drug efflux pump in extensively drug-resistant tuberculosis clinical isolates].
Cui ZL; Wang XL; Wang J; Lu JM; Hu ZY
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jul; 33(7):505-9. PubMed ID: 20979796
[TBL] [Abstract][Full Text] [Related]
31. Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model.
Cremades R; Rodríguez JC; Garcia-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
APMIS; 2011 Apr; 119(4-5):304-8. PubMed ID: 21492231
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of linezolid against Mycobacterium tuberculosis strains isoalted from Western Turkey.
Ermertcan S; Hosgor-Limoncu M; Erac B; Tasli H; Cavusoglu C; Bozkurt H
Jpn J Infect Dis; 2009 Sep; 62(5):384-5. PubMed ID: 19762990
[TBL] [Abstract][Full Text] [Related]
33. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
Vera-Cabrera L; Castro-Garza J; Rendon A; Ocampo-Candiani J; Welsh O; Choi SH; Blackwood K; Molina-Torres C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4351-3. PubMed ID: 16189119
[TBL] [Abstract][Full Text] [Related]
34. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
35. In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria.
Molicotti P; Ortu S; Bua A; Cannas S; Sechi LA; Zanetti S
New Microbiol; 2006 Oct; 29(4):275-80. PubMed ID: 17201094
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Rodriguez Díaz JC; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
[TBL] [Abstract][Full Text] [Related]
37. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
De Vecchi E; Nicola L; Ossola F; Drago L
J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
[TBL] [Abstract][Full Text] [Related]
38. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
40. Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis.
Hui M; Au-Yeang C; Wong KT; Chan CY; Yew WW; Leung CC
Int J Antimicrob Agents; 2008 Apr; 31(4):395-6. PubMed ID: 18272351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
